Increased late urinary toxicity with whole pelvic radiotherapy after prostatectomy

Radiology and Oncology

Volumn 43, Issue 2, 2009, Pages 88-96

  Kragelj, Borut ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Late toxicity; Postoperative radiotherapy; Prostate cancer; Whole pelvic radiotherapy

Indexed keywords

ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEFECATION; DYSURIA; HEMATURIA; HUMAN; INTESTINE FUNCTION; MALE; NOCTURIA; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; URINARY TRACT PAIN; URINARY URGENCY; URINE INCONTINENCE;

EID: 67650309044     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-009-0014-z     Document Type: Article

References (27)

1. Thompson IM, Tangen CM, Paradelo J, Lucia S, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 2006; 296: 2329-35.
2. Bolla M, van Poppel H, Colette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 52-8.
3. Wiegel T, Bottke D, Willich H, Piechota H, Souchon R, Stoeckle M, et al. Phase III results of adjuvant radiotherapy (RT) versus wait and see« (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95). [Abstract]. J Clin Oncol 2005; 23(Part 1 Suppl): 381S.
4. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcomes of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41.
5. Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology 2004; 64: 976-81.
6. Zelefsky MJ, Aschkenasy E, Kelesen S, Leibel SA. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Biol Phys 1997; 39: 327-33.
7. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statement on radiation therapy of prostate cancer: guidlines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Terapeutic Radiology and Oncology consensus panel. J Clin Oncol 1999; 17: 1155-63.
8. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miral bell R, Maingon P, et al. Guidlines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007; 84: 121-7.
9. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relaps-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Biol Phys 2007; 69: 54-61.
10. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Biol Phys 2000; 48: 635-42.
11. Parmar MKB, Machin D. Survival analysis. Chichester: John Wiley&Sons; 1995.
12. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton C, Michalski J, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Biol Phys 2007; 68: 1417-23.
13. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW. Effects of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Biol Phys 1998; 42: 501-6.
14. Jereczek-Fossa BA, Zerini D, Vavassori A. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2008 74: 115-25.
15. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, et al. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relaps or local recurrence after radical prostatectomy. Int J Radiat Biol Phys 2008; 72: 792-8.
16. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Biol Phys 2006; 64: 835-41.
17. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Biol Phys 2007; 69: 1100-9.
18. Portelance L, Chao KSC, Grigsby PW, Benet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum and bladder dose in patients with cervical cancer receiving pelvic and para-aortic radiation. Int J Radiat Biol Phys 2001; 51: 261-6.
19. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Biol Phys 2000; 48: 1613-21.
20. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in bladder and prostate cancer. Eur Urol Suppl 2005; 4: 15-24.
21. Roach M 3rd, Marquez C, Yuo HS. Predicting the risk of lymph node involvement using the pretreatment prostatic specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Biol Phys 1994; 28: 33-7.
22. Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anathomy. Int J Radiat Biol Phys 2005; 63: 1262-9.
23. Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-13. Urology 1999; 54: 495-502.
24. Taussky D, Bae K, Bahary JP. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology 2008; 72: 1125-9.
25. Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Biol Phys 1995; 31: 1341-6.
26. Botros M, Quevedo JF, Miller RC. Angiosarcoma of the liver after multimodality therapy for gallbladder carcinoma. Radiol Oncol 2009; 43: 126-31.
27. Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008: 42: 207-14.